Company BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:58:18 2026-10-16 EDT			5-day change	1st Jan Change
4.880 ^CAD	-8.96%		-13.01%	-50.20%

09-14	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor	CI
09-11	Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer	CI

Business description: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Number of employees: 16

Sales by Activity: BriaCell Therapeutics Corp.

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: BriaCell Therapeutics Corp.

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: BriaCell Therapeutics Corp.

Manager	Title	Age	Since
William Williams CEO	Chief Executive Officer	70	2016-10-31
Gadi Levin DFI	Director of Finance/CFO	54	2016-01-31
Guiseppe Del Priore CTO	Chief Tech/Sci/R&D Officer	65	2022-02-15
Miguel Lopez-Lago CTO	Chief Tech/Sci/R&D Officer	56	2021-04-30

See BRIACELL THERAPEUTICS CORP. governance

Composition of the Board of Directors: BriaCell Therapeutics Corp.

Director	Title	Age	Since
William Williams BRD	Director/Board Member	70	2016-10-31
Jamieson Bondarenko CHM	Chairman	41	2019-04-23
Rebecca Taub BRD	Director/Board Member	74	2019-03-06
Vaughn Embro-Pantalony BRD	Director/Board Member	68	2019-03-17
Martin Schmieg BRD	Director/Board Member	63	2016-05-09
Jane Gross BRD	Director/Board Member	69	2022-01-17

Composition of the Board of Directors

Shareholders: BriaCell Therapeutics Corp.

Name	Stocks	%	Valuation
Citadel Advisors LLC 8.238 %	716,699	8.238 %	3 M $
Cable Car Capital LP 2.492 %	216,821	2.492 %	927 994 $
Sabby Management LLC 0.9279 %	80,721	0.9279 %	345 486 $
Iridian Asset Management LLC 0.7471 %	65,000	0.7471 %	278 200 $
UBS Group AG (13f Subfiler) 0.5016 %	43,642	0.5016 %	186 788 $

Name	Stocks	%	Valuation
Citadel Advisors LLC (13f Subfiler) -	895,864	-	1 M $
Armistice Capital LLC -	536,600	-	622 456 $
Cable Car Capital LP -	321,898	-	373 402 $
Empery Asset Management LP -	300,000	-	348 000 $
MYDA Advisors LLC -	195,821	-	227 152 $

Name	Stocks	%	Valuation
Heights Capital Management, Inc. -	313,379	-	62 049 $
Sabby Management LLC -	120,802	-	23 919 $
G1 Execution Services LLC -	114,522	-	22 675 $
HRT Financial LP -	67,935	-	13 451 $
Two Sigma Securities LLC -	15,060	-	2 982 $

List of BRIACELL THERAPEUTICS CORP. shareholders

Company details: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

Bellevue Centre

V7T 2X1, West Vancouver

+604 921 1810

http://www.briacell.com

address BriaCell Therapeutics Corp.(BCT)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRIACELL THERAPEUTICS CORP.	-8.96%	-13.01%	-71.61%	-99.58%	32.85M
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+42.79%	+64.16%	68.98B
ARGENX SE	-4.09%	-0.11%	+2.31%	+54.81%	53.15B
LONZA GROUP AG	+0.03%	+5.56%	+10.18%	+41.75%	50.83B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+29.72%	+34.13%	44.61B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.05%	+112.18%	42.53B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+258.21%	+421.57%	40.57B
CELLTRION, INC.	+6.53%	+8.02%	+15.74%	+53.94%	30.95B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+31.48%	-1.63%	25.44B
BIONTECH SE	-2.76%	-9.54%	-16.53%	-9.55%	22.66B
Average	-2.56%	-0.71%	+31.83%	+67.18%	37.98B
Weighted average by Cap.	-2.43%	-0.10%	+44.73%	+90.23%